trametinib

Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,

Abstract

Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.

Org: University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland, Fondazione IRCCS - Istituto Nazionale dei Tumori (INT), Milano, Italy, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, QLD, Australia, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy,

Abstract

Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.

Org: Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, NC, Dana-Farber Cancer Institute, Boston, MA, Columbus Oncology and Hematology Associates, Columbus, OH, Medical College of Wisconsin, Milwaukee, WI, National Cancer Institute, Bethesda, MD, Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, National Institutes of Health, Bethesda, MD, National Cancer Institute Mouse Cancer Genetics Program, Frederick, MD, City of Hope, Duarte, CA, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, University of Pennsylvania Department of Medicine, Philadelphia, PA, Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Massachusetts General Hospital, Boston, MA,

Abstract

PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.

Org: Cheminpharma,

Abstract

Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.

Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,

Abstract

Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.

Org: The Hospital for Sick Children, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, University of Alberta, University of Toronto,

Abstract

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Org: Medical University of Gdańsk, Gdańsk, Poland, International Centre for Thoracic Cancers (CICT), Gustave Roussy Cancer Center, Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine,

Abstract

An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).

Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, University of California Irvine, Comprehensive Cancer Centers of Nevada, Washington University School of Medicine in St Louis,

Abstract

Response to targeted and immune therapy in patients with NSCLC and BRAF non-V600E mutations: A retrospective, multicenter analysis within the national Network Genomic Medicine Lung Cancer (nNGM) in Germany.

Org: DKFZ-Hector Cancer Institute, Network Genomic Medicine, TU Dresden, Justus-Liebig-University, University Hospital Frankfurt,

Abstract

Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).

Org: Department of Pediatric Oncology,

Abstract

Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer.

Org: Division of Endocrinology and Diabetes, The Thyroid Center,

Abstract

A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification.

Org: Sichuan Cancer Hospital and Institute, Chengdu, China, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, University of Electronic Science and Technology of China,

Abstract

MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.

Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University School of Medicine,

Abstract

Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.

Org: Division of Oncology, Rambam health care, Haifa, Israel, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel,

Abstract

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801.

Org: Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Instituto Murciano de Investigación Sanitaria (IMIB), Hospital Universitario Clínico San Carlos,

Abstract

Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC).

Org: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,

Clinical trial

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

Status: Completed, Estimated PCD: 2022-09-30

Clinical trial

An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers

Status: Completed, Estimated PCD: 2021-09-29

Abstract

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,

Abstract

Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).

Org: National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan, Department of Medical Oncology, National Cancer Center Hospital, Chuo-Ku, Japan, Nagoya University Hospital, Nagoya-Shi Showa-Ku, Aichi, Japan, The University of Tokyo Hospital, Bunkyo-Ku, Japan,

Abstract

Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.

Org: Melanoma Institute Australia, The Netherlands Cancer Institute, Amsterdam University Medical Centers, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The Christie NHS Foundation Trust,

Abstract

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.

Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Virginia Cancer Specialists, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.

Org: BioTheryX,

Abstract

Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.

Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,

Abstract

Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.

Org: H. Lee Moffitt Cancer Center and Research Institute, Asclepius Analytics, Novartis Pharmaceuticals Corporation, Kaiser Permanente Northern California,

Abstract

Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.

Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,

Abstract

Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.

Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health, CanSino Biologics, Stockton Hematology/Oncology, Lodi,

Abstract

Combination of regorafenib with BRAF-/MEK-inhibitors for the treatment of patients with refractory melanoma brain metastases.

Org: Universitair Ziekenhuis Brussel, Netherlands Cancer Institute, Department of Medical Oncology, Vrije Universiteit Brussel (VUB)/ Universitair Ziekenhuis Brussel (UZ Brussel),

Abstract

Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members.

Org: Ohio State University Comprehensive Canvcer Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, James Thoracic Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Genomic and transcriptomic profiling of inflammatory breast cancers and non-inflammatory breast cancers in Asian women.

Org: Breast Disease Center, West China Hospital, Sichuan University, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China,

Abstract

Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.

Org: Pfizer Inc., London, United Kingdom, Kirkland, QC, Canada, Pfizer, Inc., Cambridge, MA, Pfizer,

Abstract

Real world outcomes of next generation sequencing (NGS) of progressive RAI resistant metastatic thyroid cancer and treatment of these patients with redifferentiation protocol.

Org: MedStar Washington Hospital Center, Washington University School of Medicine in St Louis, DC,

Abstract

Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.

Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,

Abstract

Effect of trametinib and anti-PD-1 combo on tumor growth and survival of KRAS-mutant lung cancer by ID1 downregulation.

Org: Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain, Pamplona, Spain, Center for Applied Medical research (CIMA), Universidad de Navarra., Pamplona, Spain, Clinica Universidad de Navarra, Pamplona/Iruña, Spain, Clinica Universidad de Navarra, Pamplona, Spain, University of Navarra, Center for Applied Medical Research, Program of Solid Tumors, Pamplona, Spain, Pamplona, Spain, Department of Oncology, Instituto Valenciano de Oncologia (IVO), Universidad Catolica de Valencia (UCV), Valencia, Spain,

Product

Trametinib + Low-Dose Dabrafenib

Product

trametinib

Product

Trametinib

Product

Dabrafenib, Trametinib, Navitoclax

Product

dabrafenib plus trametinib

Product

TAFINLAR plus trametinib

Product

trametinib monotherapy

Product

trametinib + anlotinib

Product

trametinib + PDR001

Product

Dabrafenib + Trametinib

Product

Dabrafenib + Trametinib followed by Pembrolizumab

Product

dabrafenib, trametinib, pembrolizumab

Product

Nivolumab + Dabrafenib + Trametinib

Product

BRAF & MEK inhibitors

Abstract

Effect of lymph node dissection and adjuvant therapy in patients with sentinel node+ melanoma: An observational multicenter study.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine, Nagoya University Graduate School of Medicine, Aichi Cancer Center Hospital,

Abstract

Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.

Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,

Product

targeted therapies

Product

BRAF±MEK inhibitors

Product

Docetaxel plus Trametinib

Product

trametinib, venetoclax

Product

BRAFi and MEKi

Product

BRAFi/MEKi rechallenge